Reaction
Bronchiolitis Obliterans Syndrome reporting signals
As of the last recalculation, Bronchiolitis Obliterans Syndrome appears in 167 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is BUSULFAN (PRR 402.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Busulfan | 39 | 402.7 | 403.7 |
| Sirolimus | 22 | 234.3 | 234.6 |
| Thiotepa | 16 | 230.8 | 231.2 |
| Posaconazole Delayed-Release | 18 | 228.8 | 229.2 |
| Fludarabine Phosphate | 47 | 206.9 | 207.2 |
| Ruxolitinib | 61 | 166.6 | 166.7 |
| Posaconazole | 18 | 154.6 | 154.8 |
| Anti-Thymocyte Globulin (Rabbit) | 9 | 146.9 | 147.1 |
| Alemtuzumab | 19 | 138.0 | 138.2 |
| Prednisolone Acetate | 10 | 128.1 | 128.2 |
| Ganciclovir Sodium | 9 | 112.0 | 112.1 |
| Moxifloxacin | 11 | 104.1 | 104.2 |
| Ganciclovir | 8 | 102.3 | 102.4 |
| Clobetasol Propionate Ointment Usp, 0.05% | 7 | 88.4 | 88.4 |
| Clobetasol Propionate | 7 | 88.0 | 88.1 |
| Micafungin Sodium | 4 | 60.2 | 60.2 |